Comments
Cadila Healthcare Ltd (Zydus Cadila) on Friday said it has received final approval from the USFDA to market Fluconazole tablets USP and Clobetasol Propionate spray.
In a statement here, the company said Fluconazole tables, used in the treatment of fungal infections, and manufactured at the Baddi facility, will be sold in the USA in the strengths of 50, 100, 150 and 200 mg.
Clobetasol Propionate spray, used in the treatment of various skin disorders, and manufactured at the Changodar facility, will be sold in the strength of 0.05%.
The Zydus Group now has more than 105 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.